News
NCI may ‘kill’ major mammography trial, says adviser
- Author:
- Nick Mulcahy
An advisory group to the National Cancer Institute is reviewing the “feasibility and relevance” of the ongoing...
News
Hair dye and cancer study ‘offers some reassurance’
- Author:
- Nick Mulcahy
The largest study of its kind found that, with the exception of breast and ovarian cancers, there is no tie...
News
ASCO says ‘no’ to home infusions of cancer treatment, with exceptions
- Author:
- Nick Mulcahy
The American Society of Clinical Oncology has warned against intravenous infusion of chemotherapy and monoclonal antibodies in cancer patients’...
News
FDA approves triple drug combo for melanoma
- Author:
- Nick Mulcahy
Atezolizumab plus cobimetinib and vemurafenib is now approved for BRAF V600mutation-positive advanced melanoma...
News
In a first, proton therapy bests radiotherapy in an RCT
- Author:
- Nick Mulcahy
Less toxicity was observed with proton beam therapy than with conventional radiotherapy.
News
FDA okays new CAR T therapy, first for mantle cell lymphoma
- Author:
- Nick Mulcahy
The FDA granted accelerated approval to brexucabtagene autoleucel, the first approved chimeric antigen receptor...
News
Could being active reduce cancer death risk from alcohol?
- Author:
- Nick Mulcahy
Regular physical activity may reduce the risk of death from alcohol-related cancers.
News
FDA approves in-home breast cancer treatment
- Author:
- Nick Mulcahy
The FDA approved a combination of pertuzumab, trastuzumab, and hyaluronidase – administered subcutaneously – for...
News
A bumpy virtual #ASCO20; Returning to Chicago in 2021?
- Author:
- Nick Mulcahy
The ASCO annual meeting went online this year, to mixed reviews. Doubts and hopes coexist about an in-person...
News
PPI added to chemo improves breast tumor response rate
- Author:
- Nick Mulcahy
Omeprazole as an addition to treatment for triple-negative breast cancer boosted the expected rate of tumor...
News
Moving on up: Maintenance therapy extends OS in bladder cancer
- Author:
- Nick Mulcahy
Avelumab maintenance after first-line chemotherapy is a new standard of care for advanced urothelial cancer,...
News
FDA approves olaparib for certain metastatic prostate cancers
- Author:
- Nick Mulcahy
Olaparib is approved for patients with metastatic, castration-resistant prostate cancer who have deleterious/...
News
Advanced prostate cancers still rising in U.S.
- Author:
- Nick Mulcahy
New data suggest rates of regional- and distant-stage prostate cancer have increased annually in the United...
News
FDA approves ripretinib for advanced GISTs
- Author:
- Nick Mulcahy
Ripretinib is the first-ever drug specifically approved as a fourth-line treatment for advanced gastrointestinal...
News
FDA approves chemo-free combo for lung cancer
- Author:
- Nick Mulcahy
Nivolumab plus ipilimumab is approved as first-line treatment for patients with metastatic, PD-L1-positive, ALK/...